Advanced search
Publication Cover
Neuropsychiatric Disease and Treatment Volume 17, 2021 - Issue
Submit an article Journal homepage
221
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Treatment Continuation of Asenapine or Olanzapine in Japanese Schizophrenia Patients: A Propensity Score Matched Study

Haruna Matsuzaki1 Department of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
,
Masakazu Hatano1 Department of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Aichi, Japan;2 Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7032-878X
ORCID Icon,
Miko Iwata1 Department of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
&
Shigeki Yamada1 Department of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
Pages 3655-3661 | Published online: 14 Dec 2021

References

  • Robinson D, Woerner MG, Alvir JMJ, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–247. doi:10.1001/archpsyc.56.3.24110078501
  • Caseiro O, Pérez-Iglesias R, Mata I, et al. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res. 2012;46(8):1099–1105. doi:10.1016/j.jpsychires.2012.05.00122721546
  • Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology (Berl). 2016;233(14):2663–2674. doi:10.1007/s00213-016-4295-927271087
  • Orr C, Deshpande S, Sawh S, Jones PM, Vasudev K. Asenapine for the treatment of psychotic disorders: a systematic review and meta-analysis. Can J Psychiatry. 2017;62(2):123–137. doi:10.1177/070674371666132427481921
  • Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. doi:10.1016/S0140-6736(19)31135-331303314
  • Citrome L. Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014;10(6):893–903. doi:10.1517/17425255.2014.90818524793403
  • Kemp DE, Zhao J, Cazorla P, et al. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder. J Clin Psychiatry. 2014;75(3):238–245. doi:10.4088/JCP.12m0827124499969
  • Balaraman R, Gandhi H. Asenapine, a new sublingual atypical antipsychotic. J Pharmacol Pharmacother. 2010;1(1):60–61. doi:10.4103/0976-500X.6453821808592
  • Zhou M, Derakhshanian S, Rath A, et al. Asenapine transdermal patch for the management of schizophrenia. Psychopharmacol Bull. 2020;50(4):60–82.33012873
  • Kamei H, Kuno M, Takeuchi I, et al. A survey of schizophrenia patients’ satisfaction with a second-generation antipsychotic agent, sublingual asenapine. Jpn J Clin Psychopharmacol. 2018;21(11):1495–1506.
  • Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. 2015;69(8):440–447. doi:10.1111/pcn.1227525601291
  • Citrome L. Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opin Drug Saf. 2014;13(6):803–830. doi:10.1517/14740338.2014.90818324793161
  • Vieta E, Montes JM. A review of asenapine in the treatment of bipolar disorder. Clin Drug Investig. 2018;38(2):87–99. doi:10.1007/s40261-017-0592-2
  • Gerrits M, De Greef R, Peeters P. Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects. Biopharm Drug Dispos. 2010;31(5–6):351–357. doi:10.1002/bdd.71820549835
  • Hatano M, Takeuchi I, Yamashita K, et al. Satisfaction survey on antipsychotic formulations by schizophrenia patients in Japan. Clin Psychopharmacol Neurosci. 2021;19(4):610–617. doi:10.9758/cpn.2021.19.4.61034690116
  • Quinn TJ, Myint PK, McCleery J, Taylor-Rowan M, Stewart C. Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome. Cochrane Database Syst Rev. 2020;2020(2). doi:10.1002/14651858.cd013521

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.